Back to News
Market Impact: 0.05
EURETINA: PulseSight Therapeutics to Present Results of Phase 1 clinical trial of PST-611 treatment for dry AMD/Geographic Atrophy (GA)
Source: GlobeNewswire
Healthcare & Biotech
The article only states that a late-breaking oral presentation is scheduled for the 26th EURETINA Congress in Vienna from 1-4 October 2026. It provides no clinical data, company details, financial metrics, or market-moving information.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- ‘Like Kashmir’: How a toxic marble dump yard became a tourist spot in India
- Swiss firms plan to expand China investments as trade deal deepens ties
- Gaza doctors struggle with bereavement, overwork, trauma amid genocidal war
- OmniAb: A Self-Funding Option Book On 433 Partner Programs
- Regeneron: 3 Key Takeaways for Long-Term Investors
- AbbVie: 3 Key Takeaways for Long-Term Investors